微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | 47.32% | -1.04% | 1.2% | 80/159 | 50.44% | 迪哲医药 | 99.22% | 行业排名> |
| 2026-06-30 | 46.76% | -3.73% | 2.03% | 81/159 | 48.66% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 45.83% | -1.19% | -2.24% | 84/159 | 50.28% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 46.88% | -1.14% | -1.97% | 82/159 | 50.37% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 47.82% | 0.36% | -1.55% | 80/159 | -2.13% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 48.57% | 1.69% | 4.72% | 77/159 | 15.05% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 46.39% | -2.07% | -2.18% | 77/159 | 31.79% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 47.42% | -0.88% | -0.48% | 86/159 | 51.61% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 47.65% | -5.83% | -0.25% | 82/159 | 22.43% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 47.77% | -5.33% | 0.85% | 82/159 | 32.96% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 47.37% | -2.89% | -0.99% | 81/159 | 51.47% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 47.84% | -1.63% | -5.45% | 83/159 | 51.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 50.6% | -1.19% | 0.28% | 75/159 | 32.31% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 50.46% | -1.43% | 3.45% | 77/159 | 38.22% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 48.78% | -7.64% | 0.29% | 79/159 | 52.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 48.63% | 17.28% | -5.03% | 87/159 | 53.51% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 51.21% | 26.38% | 0.03% | 75/159 | 5.67% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 51.19% | 27.94% | -3.07% | 80/159 | 20.91% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 52.81% | 32.42% | 27.36% | 74/159 | 54.06% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 41.47% | -10.77% | 2.34% | 95/159 | 54.9% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 40.52% | -17.8% | 1.26% | 89/159 | 46.49% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 40.01% | -24.45% | 0.33% | 99/159 | 46.97% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 39.88% | -28.34% | -14.19% | 84/159 | 53.79% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 46.48% | 0.75% | -5.72% | 87/159 | -147.51% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 49.29% | 11.02% | -6.93% | 69/159 | 56.06% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 52.96% | 21.49% | -4.83% | 66/159 | 53.85% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 55.65% | 32.44% | 20.64% | 50/159 | 54.83% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 46.13% | 4.66% | 3.9% | 86/159 | -1232.76% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 44.4% | -1.95% | 1.85% | 69/159 | 54.86% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 43.59% | -10.17% | 3.74% | 74/159 | 54.88% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 42.02% | -25.67% | -4.67% | 70/159 | 50.75% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 44.08% | -22.99% | -2.66% | 84/159 | -210.26% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 45.28% | -19.92% | -6.69% | 62/159 | 53.75% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 48.53% | -9.45% | -14.16% | 58/159 | 53.16% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 56.53% | 1.04% | -1.23% | 46/159 | 53.78% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 57.23% | 13.22% | 1.21% | 51/159 | 52.25% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 56.55% | 16.82% | 5.51% | 34/159 | 48.76% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 53.59% | 11.11% | -4.22% | 39/159 | 47.61% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 55.95% | 27.29% | 10.69% | 29/159 | 46.62% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 50.55% | 25.15% | 4.43% | 49/159 | 48.17% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 48.4% | 20.87% | 0.36% | 32/159 | 45.83% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 48.23% | 21.53% | 9.73% | 37/159 | 45.93% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 43.96% | 7.36% | 8.82% | 36/159 | 43.86% | 贝达药业 | 97.01% | 行业排名> |